



Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference

August 27, 2020

PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- **Advaxis, Inc. (Nasdaq: ADXS)**, a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the LD Micro 500 Virtual Conference, being held virtually September 1 – 4, 2020.

Presentation Information:

Date: Wednesday, September 2nd

Time: 3:40 pm ET

Webcast: <https://www.webcaster4.com/Webcast/Page/2019/36689>

About Advaxis, Inc.

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated *Listeria monocytogenes* (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

Investor Contact

Tim McCarthy

LifeSci Advisors, LLC

Tim@lifesciadvisors.com

(212) 915-2564

ADVAXIS
IMMUNOTHERAPIES™

Source: Advaxis, Inc.